Dexmedetomidine and Long-term Outcomes in Elderly Patients After Cardiac Surgery

• Status: Active, not recruiting
• Trial end date: 2021-12-31
• Target enrollment: 0
• Participant gender: All

Summary

A retrospective study showed that intraoperative dexmedetomidine administration was associated with decreased risk of 1-year mortality after cardiac surgery. In a previous randomized controlled trial, 285 elderly patients undergoing cardiac surgery were randomized to receive either perioperative dexmedetomidine or placebo (normal saline) administration. The purpose of this 6-year follow-up study is to investigate whether perioperative dexmedetomidine can improve long-term outcomes in those recruited elderly patients after cardiac surgery.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Peking University First Hospital
• Collaborator: Chinese Academy of Medical Sciences, Fuwai Hospital
• Treatments: Dexmedetomidine

Criteria

Inclusion Criteria:

1. Age of 60 years or older;

2. Scheduled to undergo cardiac surgery (coronary artery bypass graft and/or valve replacement surgery);

3. Provide written informed consents.

Exclusion Criteria: Patients who meet any of the following criteria will be excluded.

1. Preoperative history of schizophrenia, epilepsia, Parkinson syndrome, or severe dementia;

2. Inability to communicate in the preoperative period because of severe visual/auditory dysfunction or language barrier;

3. History of brain injury or neurosurgery;

4. Preoperative sick sinus syndrome, severe bradycardia (HR < 50 bpm), second-degree or above atrioventricular block without pacemaker;

5. Severe hepatic dysfunction (Child-Pugh class C);

6. Severe renal dysfunction (requirement of renal replacement therapy);

7. Other conditions that are considered unsuitable for participation.